Pancreatic Cancer Market is Expected to Showcase a Significant Growth During the Forecast Period (2022-2032), Predicts DelveInsight | Key Companies - ImmunityBio, Cornerstone Pharma, Immix Biopharma, AB Science, BioLineRx, Novartis, FibroGen, Rain Oncolog

As per DelveInsight, the Pancreatic Cancer Market is anticipated to evolve immensely in the coming years owing to the rising incidence, increasing global healthcare investment and funding, and the ongoing development of precision medicine.

DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pancreatic Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pancreatic Cancer market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Pancreatic Cancer: An Overview
Pancreatic cancer is one of the most lethal malignant tumor types, being 4th and 5th leading cause of cancer death in the US and EU, respectively. Advanced/Metastatic pancreatic cancer means the cancer has spread from where it started, and this process is known as metastasis or has come back sometime after treatment (recurrence) it cannot be cured at this stage, but certain treatment options might control it, help symptoms, and improve quality of life for some time. Usually, after metastasis, pancreatic cancer spreads to the liver and the lungs.

A clinical/radiographic stage classification for pancreatic cancer suggests a three-stage classification (potentially resectable, locally advanced, and metastatic) of metastatic pancreatic cancer involvement based on radiological findings. The staging system used most often for pancreatic cancer is the AJCC (American Joint Committee on Cancer) TNM system which includes:- the extent of the tumor (T), the spread to nearby lymph nodes (N), the spread (metastasized) to distant sites (M).

Pancreatic Cancer Market Key Facts
• The market size of pancreatic cancer in the 7MM was observed to be USD 1,649 million in 2021.
• In 2021, the market size of pancreatic cancer in the US was USD 858 million.
• Among the EU-5 countries, Germany had the highest market size for pancreatic cancer in 2021, i.e., USD 165 million. The lowest market size was estimated in Spain, with USD 61 million in 2021.
• In Japan, the market size of pancreatic cancer was observed to be USD 270 million in 2021.
• The United States and Japan accounted for 52% and 16%, respectively, of the total market size among the 7MM countries in 2021.
• In 2021, the total incident cases of pancreatic cancer in the 7MM countries were 175,767 cases, and these cases are anticipated to increase during the study period.
• Among the European countries, Germany had the highest number of incident cases of pancreatic cancer in 2021, i.e., 21,859 cases, followed by France, which had 14,989 incident cases in 2021. On the other hand, Spain had the lowest number of incident cases of pancreatic cancer, i.e., 8,566 cases in 2021. Japan had 43,170 incident cases of pancreatic cancer in 2021.

Pancreatic Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pancreatic Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Pancreatic Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Pancreatic Cancer Market will Grow by 2032:
https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pancreatic Cancer Epidemiology
The epidemiology section covers detailed insights into the historical and current Pancreatic Cancer patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Epidemiology Segmented as -
• Gender-specific cases of pancreatic cancer in the 7MM [2019-2032]
• Treatable cases of pancreatic cancer in the 7MM [2019-2032]
• Total Incident cases of pancreatic cancer in the 7MM [2019-2032]
• Stage-wise cases of pancreatic cancer in the 7MM [2019-2032]

Get Key Insights Into the Evolving Pancreatic Cancer Epidemiology Trends:
https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pancreatic Cancer Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pancreatic Cancer market or expected to be launched during the study period. The analysis covers Pancreatic Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Pancreatic Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Recent Key Update in the Pancreatic Cancer Therapeutics Market
On APR 14, 2023, RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT) announced that it will present detailed, open label, planned Phase III interim data analysis of its innovative RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023, in Orlando, Florida.

Pancreatic Cancer Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Pancreatic Cancer. Currently, Novartis is leading the therapeutics market with its Pancreatic Cancer drug candidates in the most advanced stage of clinical development.

The Leading Players in the Pancreatic Cancer Therapeutics Market Include:
A2 Biotherapeutics, AB Science, Ability Pharmaceuticals SL, AC BioScience, Arcus Biosciences, Beijing Imunopharm Technology Co., Ltd., Bicara Therapeutics, Boehringer Ingelheim, Carisma Therapeutics Inc, ChemoCentryx, Cornerstone Pharmaceuticals, Crystal Genomics Inc., Cue Biopharma, Cytuvax, DEKA Biosciences, Eleison Pharmaceuticals, Eli Lilly and Company, Elicio Therapeutics, ERYtech Pharma, Eureka Therapeutics, Exelixis, FibroGen, GSK, Helsinn Healthcare SA, Immodulon Therapeutics Ltd, Immuneering Corporation, Jazz Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Klus Pharma Inc., Mainline Biosciences, Merck Sharp & Dohme LLC, Nelum Corp, Novartis AG, Ono Pharmaceutical, Opna Bio, Panbela Therapeutics, pHion Therapeutics Ltd., Pionyr Immunotherapeutics, Rain Oncology, Redx Pharma Plc, Roche, Senhwa Biosciences, Taiho Pharmaceutical Co., Ltd., TheraVectys, TriSalus Life Sciences, Turning Point Therapeutics, Wellmaker Bio, and many others.

Pancreatic Cancer Emerging and Marketed Drugs Covered in the Report Include:
• Anktiva (N-803): ImmunityBio
• Devimistat: Cornerstone Pharmaceuticals
• IMX-110: Immix Biopharma
• Masitinib: AB Science
• Motixafortide (BL-8040): BioLineRx
• NIS793: Novartis AG
• OSE2101: OSE Immunotherapeutics
• Pamrevlumab: FibroGen
• RAIN-32: Rain Oncology
• SBP-101: Panbela Therapeutics
• TAS-102: Taiho Pharmaceutical Co., Ltd.
And Many More

Learn More About the Emerging Therapies & Key Companies in the Pancreatic Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pancreatic Cancer Competitive Intelligence Analysis
4. Pancreatic Cancer Market Overview at a Glance
5. Pancreatic Cancer Background and Overview
6. Pancreatic Cancer Patient Journey
7. Pancreatic Cancer Epidemiology and Patient Population
8. Pancreatic Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Pancreatic Cancer Unmet Needs
10. Key Endpoints of Pancreatic Cancer Treatment
11. Pancreatic Cancer Marketed Products
12. Pancreatic Cancer Emerging Therapies
13. Pancreatic Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Pancreatic Cancer Market Outlook (7 major markets)
16. Pancreatic Cancer Access and Reimbursement Overview
17. KOL Views on the Pancreatic Cancer Market.
18. Pancreatic Cancer Market Drivers
19. Pancreatic Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.